Largest ever study« confirms efficacy of medical cannabis in cancer treatment

A study published in Frontiers in Oncology, presented as the largest-ever meta-analysis on the subject,analyzed data from over 10,000 peer-reviewed studies.

It reveals what the researchers call «the« overwhelming scientific consensus »The company's "Cannabis for Life" campaign promotes the therapeutic benefits of cannabis, particularly in oncology.

A solid analysis based on 10,641 studies

The four-person research team, representing the Whole Health Oncology Institute based in Hawaii and Chopra Foundation in New York, conducted a meta-analysis of 10,641 studies, ten times more than the second largest review ever carried out on the subject.

Their conclusion? Scientific research strongly supports the use of medical cannabis to relieve cancer-related symptoms, and even hints at its potential as an anti-cancer agent.

«We expected controversy. What we found was an overwhelming scientific consensus,» said Ryan Castle, research director at Whole Health Oncology Institute and principal author of the article.

A three-to-one ratio in favor of efficiency

According to the Whole Health Oncology Institute, For each study showing the ineffectiveness of cannabis, three others demonstrated its effectiveness ».

The authors go so far as to assert that the level of scientific consensus around the cannabis rivals that of the FDA-approved drugs, and even exceeds it. Their data show that support for medical cannabis was 31.38 times stronger than the opposition in existing literature.

Although the analysis looked at a wide range of cancer-related data, several therapeutic effects keys stood out:

• Inhibition of cancer cells
• Metastasis reduction (cancer spread)
• Induction of apoptosis (natural death of cancer cells)
• Strong anti-inflammatory action

This last point is particularly important, since the’chronic inflammation is linked to more than 80 % of the world's most disabling diseases.

«Cannabis has a well-established role in the management of cancer-related symptoms and may have direct and indirect anti-cancer properties,» said the researchers.

Consensus beyond pain relief

Cannabis has long been recognized for its ability to relieve pain, the nausea and the loss of appetite, These are the classic side effects of chemotherapy and other aggressive cancer treatments.

This new meta-analysis goes one step further. By applying sentiment analysis techniques, the researchers were able to measure the consensus between thousands of studies based on the tone and language used by the authors. scientists discuss cannabis and cancer.

The study revealed «a significant consensus in favor of the use of medical cannabis in the categories of health indicators, cancer treatments and cancer dynamics».

According to the article, «the consistent correlation between cannabis as a palliative supplement and anti-cancer agent redefines the consensus around cannabis as a medical intervention».

In short, cannabis is no longer seen simply as a means of helping patients to feel better there's growing evidence that it may in fact be help fight the disease itself.

Legal implications and call for reclassification

Beyond its medical findings, the study also raises a number of political implications urgent. The authors claim that their findings could and should influence the legal status of cannabis, particularly in jurisdictions where there is still a large substance classified in category I.

«The strong consensus in favor of the therapeutic use of cannabis, particularly in the context of cancer, suggests that there is a sound scientific basis for re-evaluating the legal status of cannabis,» the study notes.

Despite these convincing results, the researchers took to recognize limitations of their methodology, in particular the use of’computer-aided sentiment analysis. They noted that these tools can sometimes misinterpret complex medical language or fail to distinguish between negative results of the disease itself and neutral or positive evaluations of the cannabis-based treatments.

«This is particularly relevant in the medical literature, where negative sentiment in a given context, such as a description of disease progression, does not necessarily imply a negative evaluation of a treatment or intervention,» the authors wrote.

Consequently, they invite future researchers to validate the results of sentiment analysis using traditional examination methods and to interpret results «in the broader context of the literature».

The authors conclude that their work «lays the groundwork for future research and policy decisions that could have a significant impact on the public health and patient care ».

A new chapter for medical cannabis?

In the light of this analysis, the once controversial idea that the cannabis has a legitimate place in the cancer treatment is now backed up by an impressive volume of scientific data.

The Whole Health Oncology Institute presents this as a decisive turning point: «This is one of the clearest and most spectacular validations of medical cannabis in the treatment of cancer that the scientific community has ever known.»